Adoptive T cell therapy for ovarian cancer

• Published in: Gynecologic oncology 2024-07, Vol.186, p.77-84
• Main Authors: Gitto, Sarah B., Ihewulezi, Chibuike J.N., Powell, Daniel J.
• Format: Article
• Language: English
• Subjects: Adoptive cell therapy; Cancer vaccine; CAR T cell; Ovarian cancer; T cells; TCR; TILs
• ISSN: 0090-8258; 1095-6859; 1095-6859
• DOI: 10.1016/j.ygyno.2024.04.001

Although ovarian cancer patients typically respond to standard of care therapies, including chemotherapy and DNA repair inhibitors, the majority of tumors recur highlighting the need for alternative therapies. Ovarian cancer is an immunogenic cancer in which the accumulation of tumor infiltrating lymphocytes (TILs), particularly T cells, is associated with better patient outcome. Thus, harnessing the immune system through passive administration of T cells, a process called adoptive cell therapy (ACT), is a promising therapeutic option for the treatment of ovarian cancer. There are multiple routes by which tumor-specific T cell products can be generated. Dendritic cell cancer vaccines can be administered to the patients to induce or bolster T cell responses against tumor antigens or be utilized ex vivo to prime T cells against tumor antigens; these T cells can then be prepared for infusion. ACT protocols can also utilize naturally-occurring tumor-reactive T cells isolated from a patient tumor, known as TILs, as these cells often are heterogeneous in composition and antigen specificity with patient-specific cancer recognition. Alternatively, T cells may be sourced from the peripheral blood, including those that are genetically modified to express a tumor antigen-specific T cell receptor (TCR) or chimeric antigen receptor (CAR) to redirect their specificity and promote their activity against tumor cells expressing the target tumor antigen. Here, we review current ACT strategies for ovarian cancer and provide insights into advancing ACT therapy strategies for the treatment of ovarian cancer. •Ovarian cancer is immunogenic and tumor infiltrating lymphocytes (TILs) are a prognostic biomarker for patient outcomes.•Adoptive cell therapies (ACTs) are promising therapeutic approaches for ovarian cancer.•Optimization of ACT strategies in ovarian cancer is needed for increased clinical efficacy and safety.